论文部分内容阅读
１９９３年１１月～１９９５年７月，以α－２ｂ干扰素治疗骨、软组织实体瘤及转移癌４１例。其中３１例瘤内注射，１０例肌肉或皮下注射。结果显示：１）α－２ｂ干扰素对多种骨、软组织肿瘤及转移癌有较明显的局部及区域疗效，尤以恶性黑色素瘤为佳。２）瘤内注射疗效显著且肿瘤细胞及亚细胞结构有明显变化，全身用药难达此效。３）决定局部疗效的重要因素为瘤内药物浓度，而它受肿瘤体积、范围及用药途径等因素影响。４）瘤内注射后瘤组织ＣＤ４／ＣＤ８变化比较外周血ＣＤ４／ＣＤ８明显，但与某些报告不一致，其变化与疗效间亦无平行关系。提示ＣＤ４／ＣＤ８可能不适合做为衡量疗效的确切指标。
From November 1993 to July 1995, 41 patients with bone and soft tissue solid tumors and metastases were treated with α-2b interferon. Of these, 31 were intratumoral injections and 10 were injected intramuscularly or subcutaneously. The results showed that: 1) α-2b interferon has obvious local and regional effects on a variety of bone, soft tissue tumors and metastatic cancers, especially malignant melanoma. 2) The efficacy of intratumoral injection is significant and the tumor cells and subcellular structures have significant changes, and systemic medications are difficult to achieve this effect. 3) The important factor in determining the local therapeutic efficacy is the intratumoral drug concentration, which is influenced by factors such as tumor volume, range, and route of administration. 4) The change of CD4/CD8 in tumor tissue after intratumoral injection was more obvious than that in peripheral blood, but it was inconsistent with some reports, and there was no parallel relationship between its change and efficacy. Tips CD4/CD8 may not be suitable as an exact measure of efficacy.